Premium
Plasma half‐life of phenylbutazone in patients with impaired liver function
Author(s) -
Hvidberg Eigill F.,
Andreasen Per Buch,
Ranek Leo
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974152171
Subject(s) - phenylbutazone , cirrhosis , metabolite , half life , medicine , elimination rate constant , gastroenterology , oxyphenbutazone , oral administration , liver function , endocrinology , pharmacokinetics , chemistry , pharmacology , volume of distribution
In 6 patients with cirrhosis at the liver and 5 control patients, the serum concentrations of phenylbutazone (pbz) and a major metabolite, oxphenylbutazone (ox‐pbz), were followed for 16 days after oral administration of fixed doses of pbz for 4 days (600, 600,300,300 mg). Preliminary evidence is presented for a significant correlation between the apparent elimination rate constant of pbz (the plasma half‐life) and the galactose elimination capacity (r = 0.868, P < 0.05) in cirrhotic patients. The ratio between the peak concentrations at pbz and ox‐pbz in the two groups was not different.